Short Interest in Traws Pharma, Inc. (NASDAQ:TRAW) Drops By 24.2%

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 9,700 shares, a drop of 24.2% from the September 30th total of 12,800 shares. Based on an average trading volume of 9,200 shares, the short-interest ratio is currently 1.1 days. Currently, 0.3% of the shares of the stock are short sold.

Traws Pharma Stock Down 2.1 %

NASDAQ:TRAW traded down $0.10 during trading hours on Friday, hitting $4.96. The company’s stock had a trading volume of 9,609 shares, compared to its average volume of 5,788. The firm has a market capitalization of $9.07 million, a PE ratio of -0.04 and a beta of 1.37. Traws Pharma has a twelve month low of $4.44 and a twelve month high of $27.50.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($4.87) earnings per share for the quarter. Traws Pharma had a negative return on equity of 144.95% and a negative net margin of 60,641.14%. The firm had revenue of $0.06 million for the quarter. On average, analysts anticipate that Traws Pharma will post -146 EPS for the current fiscal year.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.